Formation of itraconazole-succinic acid cocrystals by gas antisolvent cocrystallization

AAPS PharmSciTech. 2012 Dec;13(4):1396-406. doi: 10.1208/s12249-012-9866-4. Epub 2012 Oct 9.

Abstract

Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO(2) to improve itraconazole dissolution. In this study, itraconazole and succinic acid were simultaneously dissolved in a liquid solvent, tetrahydrofuran, at ambient conditions. The solution was then pressurized with CO(2), which decreased the solvating power of tetrahydrofuran and caused crystallization of itraconazole-succinic acid cocrystals. The cocrystals prepared by GAS cocrystallization were compared to those produced using a traditional liquid antisolvent, n-heptane, for crystallinity, chemical structure, thermal behavior, size and surface morphology, potential clinical relevance, and stability. Powder X-ray diffraction, Fourier transform infrared spectroscopy, differential scanning calorimetry, and scanning electron microscopy analyses showed that itraconazole-succinic acid cocrystals with physical and chemical properties similar to cocrystals produced using a traditional liquid antisolvent technique can be prepared by CO(2) antisolvent cocrystallization. The dissolution profile of itraconazole was significantly enhanced through GAS cocrystallization with succinic acid, achieving over 90% dissolution in less than 2 h. The cocrystals appeared stable against thermal stress for up to 4 weeks under accelerated stability conditions, showing only moderate decreases in their degree of crystallinity but no change in their crystalline structure. This study shows the utility of an itraconazole-succinic acid cocrystal for improving itraconazole bioavailability while also demonstrating the potential for CO(2) to replace traditional liquid antisolvents in cocrystal preparation, thus making cocrystal production more environmentally benign and scale-up more feasible.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biological Availability
  • Calorimetry, Differential Scanning / methods
  • Carbon Dioxide / chemistry
  • Crystallization / methods
  • Dicarboxylic Acids / chemistry
  • Drug Stability
  • Furans / chemistry
  • Gases / chemistry
  • Heptanes / chemistry
  • Itraconazole / chemistry*
  • Particle Size
  • Powder Diffraction / methods
  • Solubility
  • Solutions / chemistry
  • Solvents / chemistry
  • Spectroscopy, Fourier Transform Infrared / methods
  • Succinic Acid / chemistry*
  • X-Ray Diffraction / methods

Substances

  • Dicarboxylic Acids
  • Furans
  • Gases
  • Heptanes
  • Solutions
  • Solvents
  • Carbon Dioxide
  • Itraconazole
  • tetrahydrofuran
  • n-heptane
  • Succinic Acid